2020
DOI: 10.4103/idoj.idoj_535_19
|View full text |Cite
|
Sign up to set email alerts
|

Co-existent erythromelanosis follicularis faciei et colli and erythroses pigmentosa mediofacialis in a patient of generalized keratosis pilaris - A rare report in a young female

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

4
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(7 citation statements)
references
References 21 publications
(17 reference statements)
4
3
0
Order By: Relevance
“…The onset of the reaction varied from a few days to 6 months. Some patients had asymptomatic lesions without relevant inflammatory signs or hair thinning [35,36,41,42], as in our case, with similar histopathological findings that were available for two patients [35,41]. In fact, in both reports [35,41], histopathological features were suggestive of KP, being characterized by keratotic plugs within the follicle and mild lymphocytic infiltration without fibrosis.…”
Section: Discussionsupporting
confidence: 80%
See 4 more Smart Citations
“…The onset of the reaction varied from a few days to 6 months. Some patients had asymptomatic lesions without relevant inflammatory signs or hair thinning [35,36,41,42], as in our case, with similar histopathological findings that were available for two patients [35,41]. In fact, in both reports [35,41], histopathological features were suggestive of KP, being characterized by keratotic plugs within the follicle and mild lymphocytic infiltration without fibrosis.…”
Section: Discussionsupporting
confidence: 80%
“…The absence of cross-intolerance between imatinib and other TKIs was confirmed by other reports [36,37,[39][40][41]. In such cases, imatinib had been stopped because of resistance or intolerance [36,37,[39][40][41] (Table 1). Among the patients examined by Patel et al [24], two patients had KP-like lesions with both dasatinib and nilotinib, whereas in another patient the rash resolved after switching from nilotinib to dasatinib.…”
Section: Discussionsupporting
confidence: 74%
See 3 more Smart Citations